间歇性内分泌治疗晚期前列腺癌临床效果分析
|
摘要
目的探究间歇性内分泌法治疗晚期前列腺癌的临床效果。方法回顾性分析2013年1月至2014年3月我院收治的56例晚期前列腺癌患者的临床资料,根据治疗方法的不同将患者分为对照组和实验组各28例,对照组患者给予持续性内分泌治疗,实验组患者给予间歇性内分泌治疗。比较两组患者的临床治疗效果、不良反应发生情况和五年生存率。结果两组的治疗总有效率(92.86%vs 85.71%)和5年生存率(78.57%vs 71.43%)相比差异不显著(P>0.05),但实验组的显效率(57.14%)显著高于对照组(25.00%),差异具有统计学意义(P<0.05)。两组骨质疏松和性欲降低等不良反应发生率相比差异不显著(P>0.05),但实验组发热、贫血和食欲下降等不良反应发生率均显著低于对照组,差异具有统计学意义(P<0.05)。结论对于晚期前列腺癌患者,给予其间歇性内分泌治疗的效果好,能够显著提高患者的功能状态、生活质量,同时不良反应少,安全可靠,值得临床推广。
Objective To explore the clinical effect of intermittent endocrine therapy on advanced prostate cancer.Methods Clinical data of 56 patients with advanced prostate cancer treated in our hospital from January 2013 to March 2014 were retrospectively analyzed.All patients were divided into control group(28 cases) and experimental group(28 cases) according to different treatment method.The control group was given continuous endocrine therapy,the experimental group was given intermittent endocrine therapy.The clinical effects,adverse reactions and five-year survival rate between the two groups were compared.Results The total effective rate(92.86% vs 85.71%)and five-year survival rate(78.57% vs 71.43%) of the two groups had no statistical difference(P >0.05),but the marked effective rate of the experimental group was significantly higher than that of the control group(57.14% vs 25.00%),with statistical difference(P <0.05).The incidence of osteoporosis and reduced sex drive between the two groups had no statistical difference(P >0.05),but the incidence of fever,anemia and appetite drops in the experimental group were significantly lower than those in the control group,with statistical difference(P <0.05).Conclusions For patients with advanced prostate cancer,intermittent endocrine therapy has significant effect and can greatly improve the functions and life quality of patients,with fewer adverse reactions,which is safe and reliable and deserves clinical application.
Objective To explore the clinical effect of intermittent endocrine therapy on advanced prostate cancer.Methods Clinical data of 56 patients with advanced prostate cancer treated in our hospital from January 2013 to March 2014 were retrospectively analyzed.All patients were divided into control group(28 cases) and experimental group(28 cases) according to different treatment method.The control group was given continuous endocrine therapy,the experimental group was given intermittent endocrine therapy.The clinical effects,adverse reactions and five-year survival rate between the two groups were compared.Results The total effective rate(92.86% vs 85.71%)and five-year survival rate(78.57% vs 71.43%) of the two groups had no statistical difference(P >0.05),but the marked effective rate of the experimental group was significantly higher than that of the control group(57.14% vs 25.00%),with statistical difference(P <0.05).The incidence of osteoporosis and reduced sex drive between the two groups had no statistical difference(P >0.05),but the incidence of fever,anemia and appetite drops in the experimental group were significantly lower than those in the control group,with statistical difference(P <0.05).Conclusions For patients with advanced prostate cancer,intermittent endocrine therapy has significant effect and can greatly improve the functions and life quality of patients,with fewer adverse reactions,which is safe and reliable and deserves clinical application.
引文
[1]袁佳奇,徐涛,张晓威,等.前列腺癌患者内分泌治疗后代谢异常及生活质量的评价[J].中国医学科学院学报,2013,35(1):88-94.
[2]巩传凤,刘畅,王岚,等.老年中晚期前列腺癌同期调强放疗联合内分泌治疗的疗效[J].中国老年学杂志,2014,34(10):2744-2745.
[3]熊太林,贺大林,樊桂玲,等.前列腺癌患者内分泌治疗后1年内进展为去势抵抗性前列腺癌的相关因素分析[J].中华泌尿外科杂志,2014,35(5):341-345.
[4]瞿元元,叶定伟,戴波,等.前列腺癌组织中雄激素受体剪接变异体7表达对转移性前列腺癌患者激素敏感时间的预测作用[J].中华泌尿外科杂志,2014,35(8):596-600.
[5]赵化荣,热合曼·衣明,胡尔西旦·尼牙孜,等.新疆不同民族老年前列腺癌内分泌治疗的预后因素[J].中国老年学杂志,2013,33(24):6125-6128.
[6]贾英杰,李小江,李超,等.益气解毒祛瘀方联合内分泌治疗晚期前列腺癌临床疗效分析[J].中国中西医结合杂志,2013,33(4):448-451.
[7]孟帅,那彦群.前列腺癌内分泌治疗中阻断肾上腺源性雄激素时机的实验研究[J].中华泌尿外科杂志,2014,35(8):625-628.
[8]姚艳红,王海涛,王青山,等.雄激素受体基因(CAG)n重复多态性长度对接受初始内分泌治疗的转移性前列腺癌患者预后的影响[J].中华泌尿外科杂志,2013,34(12):901-905.
[2]巩传凤,刘畅,王岚,等.老年中晚期前列腺癌同期调强放疗联合内分泌治疗的疗效[J].中国老年学杂志,2014,34(10):2744-2745.
[3]熊太林,贺大林,樊桂玲,等.前列腺癌患者内分泌治疗后1年内进展为去势抵抗性前列腺癌的相关因素分析[J].中华泌尿外科杂志,2014,35(5):341-345.
[4]瞿元元,叶定伟,戴波,等.前列腺癌组织中雄激素受体剪接变异体7表达对转移性前列腺癌患者激素敏感时间的预测作用[J].中华泌尿外科杂志,2014,35(8):596-600.
[5]赵化荣,热合曼·衣明,胡尔西旦·尼牙孜,等.新疆不同民族老年前列腺癌内分泌治疗的预后因素[J].中国老年学杂志,2013,33(24):6125-6128.
[6]贾英杰,李小江,李超,等.益气解毒祛瘀方联合内分泌治疗晚期前列腺癌临床疗效分析[J].中国中西医结合杂志,2013,33(4):448-451.
[7]孟帅,那彦群.前列腺癌内分泌治疗中阻断肾上腺源性雄激素时机的实验研究[J].中华泌尿外科杂志,2014,35(8):625-628.
[8]姚艳红,王海涛,王青山,等.雄激素受体基因(CAG)n重复多态性长度对接受初始内分泌治疗的转移性前列腺癌患者预后的影响[J].中华泌尿外科杂志,2013,34(12):901-905.